Show Summaries | Hide Summaries
- Arena Pharmaceuticals: How Good Can It Get?
What Did Bernanke REALLY Say On June 7?
Jun. 8, 2012 • 16 Comments
- What Arena Pharmaceuticals Needs To Say To The May 10 FDA Advisory Committee
- Arena Pharma's 5-Year Revenue Forecast
- Watch Out For Gold Miners ETF Income And Capital Gains Distributions In December
Is Default Deflationary?
Dec. 4, 2011 • 14 Comments
- Zalicus Up in 2011; Expected to Rise Higher
- A Popular Economic Theory Aside, Japan's Growth Will Accelerate
- What's Next for Zalicus After Fourth Quarter Results?
- 5 Stocks for 2011
- Arena's Weight Loss Drug Faces Relatively Easy Path to Approval
- Why Bernanke Can't Win, But Will Kill the Dollar Trying
- BioCryst Drug Receives Recommendation for Pediatric Approval in Japan
Can the Fed Funds Rate Go Negative?
Aug. 30, 2010 • 8 Comments
- Is Dow 1,000 a Possibility?
- BioCryst: Peramivir Approval Opens Japanese Market
- BioCryst: Israel Orders 150 Doses of H1N1 Antiviral Peramivir
- BioCryst: H1N1 Antiviral Partner Gets Fast Tracked for Japanese Review
- BioCryst's Korean Partner Receives Emergency Use Authorization
- Investing in the Obesity Drug Basket
- Look - It's a V-Shaped Recovery
- Why the Recession Is Over
- Bad News? They're Just Lagging Indicators
- A Biotech Triple Play: Dendreon, BioCryst and Arena
- Is Dendreon a $360 Stock - Or Is That Too Low?
- Heads Up on the Dollar Today: The World's Reserve Currency Is Changing
- TowerStream Corporation's Time Has Come